FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200417218> ?p ?o ?g. }

• W4200417218 endingPage "610" @default.
• W4200417218 startingPage "601" @default.
• W4200417218 abstract "Chronic obstructive pulmonary disease (COPD) with eosinophilic airway inflammation represents a distinct phenotype that might respond to treatment with inhaled corticosteroids. Fractional exhaled nitric oxide (FENO) might predict eosinophilic inflammation and guide treatment option. We hypothesized that COPD patients with different baseline levels of FENO might have differentiated response to treatment with salmeterol/fluticasone (SFC) or tiotropium (TIO). This open-label, randomized-controlled trial enrolled treatment-naïve COPD patients who were stratified into high- (≥23.5 ppb) and low-FENO group, followed by 12-week treatment with SFC or TIO. A linear mixed model with repeated measures was applied to analyze the changes in FENO (primary outcome), COPD assessment test (CAT) score, FEV1, and parameters in induced sputum and blood after treatment. 134 patients were divided into 4 subgroups: low-FENO/SFC (n = 30), low-FENO/TIO (n = 29), high-FENO/SFC (n = 37), and high-FENO/TIO (n = 38). At baseline, FENO 23.5 ppb clearly differentiated between eosinophilic and non-eosinophilic inflammation groups based on the eosinophils in induced sputum and blood. FENO significantly correlated with sputum and blood eosinophils at baseline. High-FENO/SFC (vs. high-FENO/TIO) subgroup had significant reduction in FENO and sputum inflammation profiles (including eosinophils, macrophages, matrix metalloproteinase-9, and interlukin-8) after treatment. These differences were not replicated between low-FENO/SFC and low-FENO/TIO subgroups. The improvement in CAT and FEV1 after treatment was indiscriminate between SFC and TIO in the low- and high-FENO groups. High baseline FENO can serve as an indicator of eosinophilic airway inflammation in COPD patients who may respond favorably to treatment with inhaled corticosteroids/long-acting β2-agonists. ClinicalTrials.gov Identifier: NCT02546349." @default.
• W4200417218 created "2021-12-31" @default.
• W4200417218 creator A5017257090 @default.
• W4200417218 creator A5017489241 @default.
• W4200417218 creator A5019535625 @default.
• W4200417218 creator A5024040191 @default.
• W4200417218 creator A5044121372 @default.
• W4200417218 creator A5057532204 @default.
• W4200417218 creator A5057534751 @default.
• W4200417218 creator A5077310924 @default.
• W4200417218 creator A5077396900 @default.
• W4200417218 date "2022-08-01" @default.
• W4200417218 modified "2023-09-25" @default.
• W4200417218 title "Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial" @default.
• W4200417218 cites W1760281680 @default.
• W4200417218 cites W1930109984 @default.
• W4200417218 cites W1974698157 @default.
• W4200417218 cites W1987555297 @default.
• W4200417218 cites W1987881697 @default.
• W4200417218 cites W2002615622 @default.
• W4200417218 cites W2039344685 @default.
• W4200417218 cites W2042665084 @default.
• W4200417218 cites W2048660493 @default.
• W4200417218 cites W2056032598 @default.
• W4200417218 cites W2062064850 @default.
• W4200417218 cites W2063070786 @default.
• W4200417218 cites W2066880035 @default.
• W4200417218 cites W2072649524 @default.
• W4200417218 cites W2082185102 @default.
• W4200417218 cites W2095054225 @default.
• W4200417218 cites W2095244193 @default.
• W4200417218 cites W2100578775 @default.
• W4200417218 cites W2123002410 @default.
• W4200417218 cites W2125078269 @default.
• W4200417218 cites W2133928926 @default.
• W4200417218 cites W2137890862 @default.
• W4200417218 cites W2139397407 @default.
• W4200417218 cites W2144570757 @default.
• W4200417218 cites W2150285844 @default.
• W4200417218 cites W2153057487 @default.
• W4200417218 cites W2166667839 @default.
• W4200417218 cites W2172490363 @default.
• W4200417218 cites W2474380213 @default.
• W4200417218 cites W2592919648 @default.
• W4200417218 cites W2766716690 @default.
• W4200417218 cites W2770113020 @default.
• W4200417218 cites W2877209267 @default.
• W4200417218 cites W2897466202 @default.
• W4200417218 cites W2900631531 @default.
• W4200417218 cites W2990532776 @default.
• W4200417218 cites W2998646242 @default.
• W4200417218 cites W3003551360 @default.
• W4200417218 cites W4211006694 @default.
• W4200417218 doi "https://doi.org/10.1016/j.arbres.2021.11.013" @default.
• W4200417218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35312525" @default.
• W4200417218 hasPublicationYear "2022" @default.
• W4200417218 type Work @default.
• W4200417218 citedByCount "2" @default.
• W4200417218 countsByYear W42004172182022 @default.
• W4200417218 crossrefType "journal-article" @default.
• W4200417218 hasAuthorship W4200417218A5017257090 @default.
• W4200417218 hasAuthorship W4200417218A5017489241 @default.
• W4200417218 hasAuthorship W4200417218A5019535625 @default.
• W4200417218 hasAuthorship W4200417218A5024040191 @default.
• W4200417218 hasAuthorship W4200417218A5044121372 @default.
• W4200417218 hasAuthorship W4200417218A5057532204 @default.
• W4200417218 hasAuthorship W4200417218A5057534751 @default.
• W4200417218 hasAuthorship W4200417218A5077310924 @default.
• W4200417218 hasAuthorship W4200417218A5077396900 @default.
• W4200417218 hasBestOaLocation W42004172181 @default.
• W4200417218 hasConcept C126322002 @default.
• W4200417218 hasConcept C142724271 @default.
• W4200417218 hasConcept C168563851 @default.
• W4200417218 hasConcept C2776042228 @default.
• W4200417218 hasConcept C2776301714 @default.
• W4200417218 hasConcept C2776780178 @default.
• W4200417218 hasConcept C2779758542 @default.
• W4200417218 hasConcept C2780333948 @default.
• W4200417218 hasConcept C2781069245 @default.
• W4200417218 hasConcept C2781142857 @default.
• W4200417218 hasConcept C2781212218 @default.
• W4200417218 hasConcept C71924100 @default.
• W4200417218 hasConcept C90924648 @default.
• W4200417218 hasConceptScore W4200417218C126322002 @default.
• W4200417218 hasConceptScore W4200417218C142724271 @default.
• W4200417218 hasConceptScore W4200417218C168563851 @default.
• W4200417218 hasConceptScore W4200417218C2776042228 @default.
• W4200417218 hasConceptScore W4200417218C2776301714 @default.
• W4200417218 hasConceptScore W4200417218C2776780178 @default.
• W4200417218 hasConceptScore W4200417218C2779758542 @default.
• W4200417218 hasConceptScore W4200417218C2780333948 @default.
• W4200417218 hasConceptScore W4200417218C2781069245 @default.
• W4200417218 hasConceptScore W4200417218C2781142857 @default.
• W4200417218 hasConceptScore W4200417218C2781212218 @default.
• W4200417218 hasConceptScore W4200417218C71924100 @default.
• W4200417218 hasConceptScore W4200417218C90924648 @default.
• W4200417218 hasFunder F4320307773 @default.
• W4200417218 hasIssue "8" @default.

• next